OSR Health, Inc. announced it is preparing a formal appeal to the Nasdaq Independent Hearings Panel after receiving a delisting determination on August 19, with plans to submit its hearing request by August 26. The company also highlighted its $15 million Put Option exercisable against BCM Europe AG from October 29, 2026, at $10.00 per share, which it says reflects a third-party institutional valuation of its VXM01 asset. CEO Peter Hwang stated that the option remains unchanged and that management is in active communication with BCM Europe's Korean end investors regarding settlement capacity. OSR Health's subsidiaries Woori IO and Darnatein will continue development activities, and the company plans to file a registration statement for its CVR program.
OSR Holdings IncNasdaq delisting determination and appeal process
